Semaglutide vs Tirzepatide: GLP-1 Agonist Comparison

[01dragonslayer]

Overview​

Both semaglutide and tirzepatide are FDA-approved medications for weight loss and diabetes management, but tirzepatide's dual-agonist mechanism offers distinct advantages.

Semaglutide (Ozempic, Wegovy)​

Mechanism: GLP-1 receptor agonist

FDA Approval:

• Ozempic (diabetes): 2017
• Wegovy (weight loss): 2021

Average Weight Loss: 15-17% of body weight

Dosing: Weekly subcutaneous injection (0.25mg to 2.4mg)

Primary Benefits:

• Significant weight loss
• Improved glycemic control
• Cardiovascular benefits
• Reduced appetite
• Slower gastric emptying

Tirzepatide (Mounjaro, Zepbound)​

Mechanism: Dual GLP-1/GIP receptor agonist

FDA Approval:

• Mounjaro (diabetes): 2022
• Zepbound (weight loss): 2023

Average Weight Loss: 20-22% of body weight

Dosing: Weekly subcutaneous injection (2.5mg to 15mg)

Primary Benefits:

• Superior weight loss vs semaglutide
• Enhanced metabolic effects
• Better glucose control
• Improved insulin sensitivity
• Potential muscle preservation

Head-to-Head Comparison​

Feature	Semaglutide	Tirzepatide
Weight Loss	15-17%	20-22%
Mechanism	GLP-1 only	GLP-1 + GIP
Nausea Rate	20-30%	15-25%
Cost	$$$	$$$$
Track Record	Longer (2017)	Newer (2022)
Muscle Preservation	Moderate	Better
A1C Reduction	1.5-2.0%	2.0-2.5%

Clinical Trial Results​

STEP Trials (Semaglutide):

• Average 15.3% weight loss at 68 weeks
• 86% achieved ≥5% weight loss
• Significant cardiovascular benefits

SURMOUNT Trials (Tirzepatide):

• Average 22.5% weight loss at 72 weeks
• 91% achieved ≥5% weight loss
• Superior metabolic improvements

Side Effect Profile​

Both Medications:

• Nausea (most common, usually transient)
• Diarrhea
• Constipation
• Abdominal pain
• Fatigue

Tirzepatide Advantages:

• Slightly lower nausea rates
• Better GI tolerability in some patients

Contraindications (Both):

• Personal/family history of medullary thyroid cancer
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy/breastfeeding

Cost Considerations​

Semaglutide:

• Ozempic: ~$900-1,000/month
• Wegovy: ~$1,300-1,400/month
• Compounded: $200-400/month

Tirzepatide:

• Mounjaro/Zepbound: ~$1,000-1,100/month
• Compounded: $300-500/month

Which One to Choose?​

Choose Semaglutide If:

• Longer track record preferred
• Lower cost is priority
• Good results at lower doses
• Insurance covers it

Choose Tirzepatide If:

• Maximum weight loss desired
• Better metabolic control needed
• Muscle preservation important
• Can tolerate higher cost

Combination with Other Peptides​

Both can be stacked with:

• BPC-157 (gut protection, muscle preservation)
• CJC-1295/Ipamorelin (muscle maintenance)
• NAD+ (metabolic support)

Conclusion​

Semaglutide offers proven, significant weight loss with a longer safety track record.

Tirzepatide provides superior weight loss and metabolic benefits through its dual-agonist mechanism.

Both are excellent options—choice depends on individual goals, tolerance, and budget.